Abemaciclib is currently approved for similar indications to those of palbociclib and as monotherapy in patients with HR + / HER2 − aBC/mBC with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting [10]. The gene discussed is HR; the disease is aneurysmal bone cyst.